Research programme: tuberculosis therapies - Sanofi

Drug Profile

Research programme: tuberculosis therapies - Sanofi

Alternative Names: TB therapies - Sanofi/Global Alliance for TB Drug Development (TB Alliance); TB therapies - Sanofi/Weill Cornell Medical College

Latest Information Update: 06 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Global Alliance for TB Drug Development; Sanofi
  • Class Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Tuberculosis

Most Recent Events

  • 31 Jul 2018 Discontinued for Tuberculosis in USA (unspecified route)
  • 04 Nov 2017 No recent reports of development identified for research development in Tuberculosis in USA
  • 20 Sep 2012 Sanofi and Global Alliance for TB Drug Development entered a new collaborative agreement to accelerate discovery and development of new Tuberculosis therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top